One of the ASX’s hottest shares reports strong growth
Shane Ponraj | Morningstar
Polynovo (ASX: PNV) earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of skin when lost through surgery, trauma, burns, or other causes of tissue loss.
The shares are up more than 68% in the last year. They currently trade at a 167% premium to our fair value estimate of $1.
Polynovo is growing quickly. Fiscal 2024 sales rose 54% to $92 million, 2% ahead of our forecast, with 75% stemming from the main United States market. We raise our fair value estimate by 5% to $1.05 primarily due to the time value of money and slightly higher revenue forecasts. Our forecast five-year revenue compound annual growth rate increases to 26% from 25%. We expect the firm’s bolstered sales team to support market share gains.
Nonetheless, shares appear materially overvalued. We suspect the market is too optimistic about the speed and extent of Polynovo’s commercial rollout and the research and development spending required to stay competitive over the long term.
The burns market has many competing products and management highlights the importance of continuing to invest in R&D to future-proof the business. In addition, group profitability is likely to be diluted by lower-margin developing markets growing as a proportion of revenue. Full fiscal 2024 results and profitability will be disclosed on Aug. 23.
We think the market is also overly excited about potential new uses of Polynovo’s NovoSorb technology. While broader uses, including hernia repair and breast augmentation and reconstruction, are being considered and would greatly expand Polynovo’s addressable market, these are still very early in the development phase, with no firm timelines provided. We do not yet explicitly forecast new use cases in our base case particularly given the relatively low R&D spending directed toward these efforts to date.
Business strategy and outlook
Polynovo’s strategy revolves around expanding its geographical footprint to increase access to its products and open new hospital accounts. With its geographical reach the firm estimates its products are available to 800 million people as of fiscal 2023, but highlights the global market is underserved. The firm entered several new markets in fiscal 2023 including India, France, Spain, Canada, and Hong Kong, Polynovo intends to enter more geographies with new regulatory approvals, particularly with a focus on China and Japan through distribution partners. While the US market is key for Polynovo, representing roughly 80% of sales in fiscal 2023, new geographies would diversify the sales mix.
To support its organic top-line growth in existing and new markets, the firm invests heavily in expanding its sales staff as well as its in-house R&D. Product sales are largely through direct distribution, but Polynovo appointed distribution partners in select geographies including Germany, France, Spain, and Canada. Its R&D efforts center around exploring and receiving regulatory clearances for applications of NovoSorb products beyond the dermal substitute market.
Polynovo launched NovoSorb MTX in May 2023 to complement its main product NovoSorb BTM. NovoSorb MTX is like NovoSorb BTM but without the sealing membrane outer layer, and used in broader applications where it is not required. This is expected to drive sales with existing customers as sales staff can cross-sell products, with surgeons able to carry both products. Near-term, the firm is aiming to receive regulatory approval for full-thickness burns in the US and planning to complete recruitment of 120 patients for its associated US pivotal trial in fiscal 2024. The firm is also conducting clinical trials to receive reimbursement support for chronic diabetic foot ulcers and wounds. We think these efforts are likely to support growth.
We expect Polynovo’s NovoSorb products to pose a significant challenge to the traditional skin graft. We believe Polynovo will be successful based on the technology’s clinical performance and ease of use backed by a growing number of surgeon-led research and publications.
Fair value
Our fair value estimate for Polynovo is $1.05 per share and assumes the company is profitable from fiscal 2024 onward.
We forecast a five-year group revenue compounded annual growth rate ("CAGR") of 26% forward to fiscal 2028 versus a trailing two-year revenue CAGR of 50%. This is driven by Polynovo’s key US geography where we forecast a five-year revenue CAGR of 21% for the region.
We expect the firm increasing its sales staff to support market share gains. In addition, we expect the recent product launch of NovoSorb MTX to increase penetration within existing hospital accounts given its broader applications. Our forecast five-year revenue CAGR for geographies outside the US is 40%. This is driven by recent entries in India, France, Spain, Canada, and Hong Kong, as well as planned entries into China and Japan. As such, we forecast revenue contribution from the US to drop to 65% of group sales in fiscal 2028 from 79% in fiscal 2023.
On the profitability front, we expect group midcycle operating margins to settle at around 35% by fiscal 2033. We forecast Polynovo’s maiden profit in fiscal 2024 and margin expansion from operating leverage. Our estimates deliver EPS growth of 18% at midcycle. We forecast average annual capital expenditures of roughly AUD 6 million over the next 10 years, or 3% of group sales. We also factor $25 million in capital expenditure over fiscal 2025 and fiscal 2026 to fund a new manufacturing facility which has capacity to service an additional AUD 500 million in annual sales.
Risk and uncertainty
Our Morningstar Uncertainty Rating for Polynovo is Very High. There is risk surrounding the pace and success of Polynovo’s global sales rollout, timing, and cost needed to get potential further indications approved, and the cost base required to support the firm’s revenue ambitions. With the company still in the early stages of its commercial rollout, there is elevated uncertainty. However, the company raised capital in fiscal 2023 which we expect to tide it over until it becomes cash flow positive in fiscal 2027.
The key unknowns are regarding potential new indications and new geographies. Polynovo is targeting China and Japan as new geographies to enter but this is dependent on finding suitable distribution partners, receiving regulatory clearances, and completing registration processes. Management have also suggested potentially lowering pricing in emerging markets to increase access for patients. The firm is also exploring design options to utilize NovoSorb technology for much broader indications including hernia repair and breast augmentation and reconstruction. If successful, this would materially contribute to growing Polynovo’s addressable market.
The primary environmental, social, and governance risk to Polynovo is related to product governance, where a significant failure in quality or safety leads to a product recall or redesign. A serious failure may also expose Polynovo to patient liability claims and severe reputational damage. However, we view this as having a low likelihood given US Food and Drug Administration clearance in 2015 and a lack of noteworthy incidents given NovoSorb’s robustness in the presence of post-surgical infection. Failure to recruit or retain adequate sales talent may also contribute to declining sales growth. However, we do not think Polynovo will be challenged in managing human capital, with the company offering competitive compensation and accelerating the number of employees added over the last five years.
Access this research and more at Morningstar. For a free four-week trial, click here.
All prices and analysis at 25 July 2024. This information has been prepared by Morningstar Australasia Pty Limited (“Morningstar”) ABN: 95 090 665 544 AFSL: 240 892. The content is distributed by WealthHub Securities Limited (WSL) (ABN 83 089 718 249)(AFSL No. 230704). WSL is a Market Participant under the ASIC Market Integrity Rules and a wholly owned subsidiary of National Australia Bank Limited (ABN 12 004 044 937)(AFSL No. 230686) (NAB). NAB doesn’t guarantee its subsidiaries’ obligations or performance, or the products or services its subsidiaries offer. This material is intended to provide general advice only. It has been prepared without having regard to or taking into account any particular investor’s objectives, financial situation and/or needs. All investors should therefore consider the appropriateness of the advice, in light of their own objectives, financial situation and/or needs, before acting on the advice. Past performance is not a reliable indicator of future performance. Any comments, suggestions or views presented do not reflect the views of WSL and/or NAB. Subject to any terms implied by law and which cannot be excluded, neither WSL nor NAB shall be liable for any errors, omissions, defects or misrepresentations in the information or general advice including any third party sourced data (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the general advice or information. If any law prohibits the exclusion of such liability, WSL and NAB limit its liability to the re-supply of the information, provided that such limitation is permitted by law and is fair and reasonable. For more information, please click here.